Trivora (Levonorgestrel / Ethinyl Estradiol / Levonorgestrel / Ethinyl Estradiol / Levonorgestrel / Ethinyl Estradiol) - Summary

TRIVORA SUMMARY

PHYSICIAN LABELING
Trivora^®
(levonorgestrel and ethinyl estradiol tablets USP)
triphasic regimen
Rx only

Each Trivora cycle of 28 tablets consists of three different drug phases as follows: Phase 1 comprised of 6 blue tablets, each containing 0.050 mg of levonorgestrel (d (-)-13 beta-ethyl-17-alpha-ethinyl-17-beta-hydroxygon-4-en-3-one), a totally synthetic progestogen, and 0.030 mg of ethinyl estradiol (19-nor-17α-pregna-1,3,5(10)-trien-20-yne-3, 17-diol); phase 2 comprised of 5 white tablets, each containing 0.075 mg levonorgestrel and 0.040 mg ethinyl estradiol; and phase 3 comprised of 10 pink tablets, each containing 0.125 mg levonorgestrel and 0.030 mg ethinyl estradiol; then followed by 7 peach inert tablets.

Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.

See all Trivora indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Trivora (Levonorgestrel / Estradiol / Levonorgestrel / Estradiol / Levonorgestrel / Estradiol)

New technology combining contraception, HIV and herpes simplex virus-2 prevention
Source: HIV / AIDS News From Medical News Today [2013.11.14]
CONRAD Head of drug delivery, Meredith Clark, PhD, presented preclinical data on a new intravaginal ring that provides contraception as well as HIV-1 and HSV-2 prevention at the 2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Antonio, Texas.

Hormone levels in women using contraception affect nerve activity involved in vessel constriction
Source: Endocrinology News From Medical News Today [2013.11.10]
After menopause, women's levels of estrogen and progesterone fall. Their formerly lower risk for heart disease equals, even surpasses, men's risk. One possible contributing explanation for the change in risk is that sex hormones affect the sympathetic nervous system (SNS), which controls constriction of blood vessels and participates in the fight or flight response.

Contraception needed 3 weeks after giving birth, new mums warned
Source: Fertility News From Medical News Today [2013.10.23]
Fertility can return much more rapidly than many women assume after giving birth, and myths still abound about what contraception can and can't be used while breastfeeding.

White House Unveils Final Plan on Coverage for Contraception
Source: MedicineNet Birth Control Specialty [2013.07.01]
Title: White House Unveils Final Plan on Coverage for Contraception
Category: Health News
Created: 6/28/2013 2:36:00 PM
Last Editorial Review: 7/1/2013 12:00:00 AM

more news >>

Clinical Trials Related to Trivora (Levonorgestrel / Estradiol / Levonorgestrel / Estradiol / Levonorgestrel / Estradiol)

Effects of Administration of Fostamatinib on Blood Concentrations of an Oral Contraceptive in Healthy Female Subjects [Recruiting]
A crossover study to assess the effect of repeated doses of fostamatinib on the levels of oral contraceptive (Microgynon® 30) in the blood of healthy female subjects. The study will consist of a screening period of up to 35 days, followed by 2 treatment periods (28 days each) of an oral contraceptive (Microgynon® 30) in the absence and presence of fostamatinib. The study will also evaluate the safety and tolerability of fostamatinib in combination with an oral contraceptive

AZD6140 Oral Contraceptive Interaction Study [Recruiting]

A Study to Investigate the Potential Pharmacokinetic Interaction of Perampanel With Oral Contraceptives in Healthy Female Subjects [Recruiting]

A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil. [Completed]
The purpose of the study was to compare the contraceptive efficacy and safety of the transdermal patch to Triphasil.

A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens [Completed]
This is a randomized, open-label study to evaluate pituitary ovarian suppression in healthy, reproductive-aged women using three different regimens of oral contraceptives (OCs). Two extended regimen OCs, Seasonale (levonorgestrel/ethinyl estradiol 0. 15/0. 03 mg for 84 days followed by 7 days of placebo), and Seasonique (levonorgestrel/ethinyl estradiol 0. 15/0. 03 mg for 84 days followed by 7 days of ethinyl estradiol 0. 01 mg), and a 28-day regimen OC, Portia (levonorgestrel/ethinyl estradiol 0. 15/0. 03 mg for 21 days followed by 7 days of placebo).

more trials >>